Brands & Strategies: Dyslipidemia

Table of Contents

Brands & Strategies: Dyslipidemia

Table of Contents

Table of Exhibits

Executive Summary

• Market Summary
• Competitive Landscape
• Brand Overview
• Physician Perspectives

Section 1: Dyslipidemia Disease Dynamics

• Disease Background
• Patient Population
• Prevaence and Diagnosis
  • US Prevalence and Diagnosis
  • Europe Prevalence and Diagnosis
  • Japan Prevalence and Diagnosis
• Prescribers
• Treatment Dynamics
• Market Summary
• Reimbursement Issues

Section 2: Competitive Analysis

• Overview of Competitive Landscape
• Research and Development Spending
• Promotional Spending
• Dyslipidemia Market Messaging
• Physician Perceptions

Pfizer

• Cardiovascular and Metabolic Diseases Product Portfolio
• Goals in Cardiovascular and Metabolic Diseases Treatment
• Current Positioning
• Market Strategy
• Outlook
• Lipitor
  • Development and Commercial Overview
  • Current Positioning and Physician Perception
  • Key Brand Strategies
  • Future Positioning
• Caduet
  • Development and Commercial Overview
  • Current Positioning and Physician Perception
  • Key Brand Strategies
  • Future Positioning
• Other Pfizer Dyslipidemia Products
  • Lopid (Gemfibrozil)

Merck

• Cardiovascular Product Portfolio
• Goals in Cardiovascular Treatment
• Current Positioning
• Market Strategy
• Outlook
• Zocor
  • Development and Commercial Overview
  • Current Positioning and Physician Perception
  • Key Brand Strategies
  • Future Positioning
• Zetia
  • Development and Commercial Overview
  • Current Positioning and Physician Perception
  • Key Brand Strategies
  • Future Positioning
• Vytorin
  • Development and Commercial Overview
  • Current Positioning and Physician Perception
  • Key Brand Strategies
  • Exhibit 2-58:
  • Future Positioning
• Cordaptive
• MK-0524B

Schering-Plough

• Cardiovascular Product Portfolio
• Goals in Cardiovascular Treatment
• Current Positioning
• Market Strategy
• Outlook

Abbott

• Cardiovascular Product Portfolio
• Goals in Cardiovascular Treatment
• Current Positioning
• Market Strategy
• Outlook
• Tricor
  • Development and Commercial Overview
  • Current Positioning and Physician Perception
  • Key Brand Strategies
  • Future Positioning
• Niaspan
  • Development and Commercial Overview
  • Current Positioning and Physician Perception
  • Key Brand Strategies
  • Future Positioning
• Other Abbott Dyslipidemia Products
  • Advicor (lovastatin + ER niacin)
• Rosuvastatin/ABT-335

AstraZeneca

• Cardiovascular Product Portfolio
• Goals in Cardiovascular Treatment
• Current Positioning
• Market Strategy
• Outlook
• Crestor
  • Development and Commercial Overview
  • Current Positioning and Physician Perception
  • Key Brand Strategies
  • Future Positioning

Novartis

• Lescol

Bristol-Myers Squibb

• Pravachol

Emerging Competitors:

Takeda

• Lapaquistat

ISIS Pharmaceuticals Inc.

• ISIS-301012

Section 3: Market Forecast

• Market Overview
  • Drug Sales by Region
  • Drug Sales by Class
• Dyslipidemia Market Forecast
  • Statin Market
  • FDC Market
  • Cholesterol Absorption Inhibitor Market
  • Fibrate Market
  • Niacin Market
  • Bile Acid Sequestrants Market
  • Omega-3 Acid Ethyl Esters Market

Section 4: Appendix

• Acronyms and Abbreviations
• Methodology
  • Epidemiological Forecast Methodology
  • Market Forecast Methodology
  • Competitive Analysis Methodology
  • Survey Methodology

Table of Exhibits

Executive Summary

• Exhibit ES-1: Key Parameters of the Dyslipidemia Market
• Exhibit ES-2: Dyslipidemia Branded Market, ($US), Major Markets, 2006-2011
• Exhibit ES-3: Dyslipidemia Market Competitive Position, 2006 and 2011
• Exhibit ES-4: Statin Market Share, by Brand, 2006 and 2011
• Exhibit ES-5: Dyslipidemia Brand Sales ($US), by Brand, 2006 and 2011
• Exhibit ES-6: Physician Rankings of Companies in Dyslipidemia Treatment

Section 1: Dyslipidemia Disease Dynamics

• Exhibit 1-1: Manifestation of Dyslipidemia
• Exhibit 1-2: Prevalent and Diagnosed Dyslipidemia Cases, Major Markets
• Exhibit 1-3: Prevalent and Diagnosed Dyslipidemia Cases, US
• Exhibit 1-4: Prevalence of Dyslipidemia, Europe, 2006-2011 (Table)
• Exhibit 1-5: Prevalence of Dyslipidemia, Europe, 2006-2011 (Graph)
• Exhibit 1-6: Prevalent and Diagnosed Dyslipidemia Cases, Japan
• Exhibit 1-7: Unmet Needs in Dyslipidemia Treatment
• Exhibit 1-8: Physician Perceptions of Most Appealing Antidyslipidemic FDCs
• Exhibit 1-9: NCETP ATP III Guidelines for Cholesterol, TG, LDL and HDL Levels
• Exhibit 1-10: Major Markets Guidelines for Dyslipidemia
• Exhibit 1-11: General Treatment Algorithm for Dyslipidemia
• Exhibit 1-12: Agents Approved for the Treatment of Dyslipidemia, by Drug Class
• Exhibit 1-13: Emerging Dyslipidemia Drugs, by Drug Class
• Exhibit 1-14: Dyslipidemia Sales ($US), by Country, 2006
• Exhibit 1-15: Dyslipidemia Sales ($US), by Drug Class, 2006
• Exhibit 1-16: Dyslipidemia, Sales ($US), Market Share, by Brand, 2006
• Exhibit 1-17: Formulary Status of Antidyslipidemics in Key Plans
• Exhibit 1-18: Formulary Status of Antidyslipidemics in Key Plans (Continued)

Section 2: Competitive Landscape

• Exhibit 2-1: Physician Perception on Branded Antidyslipidemic Drugs Following the Availability of Generic Simvastatin
• Exhibit 2-2: Dyslipidemia Market Competitive Position, 2006 and 2011
• Exhibit 2-3: Dyslipidemia Market ($US), by Company, 2006-2011
• Exhibit 2-4: Dyslipidemia Market Share ($US), by Company, 2006-2011
• Exhibit 2-5: Top Six Companies in the Dyslipidemia Market, 2006 Financials
• Exhibit 2-6: Promotional Spend for Dyslipidemia Therapies, by Company, 2006
• Exhibit 2-7: Branded Statins Promotional Spending
• Exhibit 2-8: Promotional Spending for FDCs and Branded Nonstatins
• Exhibit 2-9: Various Promotional Spending for Dyslipidemia Therapies, by Brand, 2006
• Exhibit 2-10: Physician Perception of Most Influential Messaging in the Dyslipidemia Market
• Exhibit 2-11: Physician Perception of Most Influential Branded-Drug Messaging in the Dyslipidemia Market
• Exhibit 2-12: Physician Perception of Most Influential FDC Messaging in the Dyslipidemia Market
• Exhibit 2-13: Physician Perception: Most Influential Companies in Dyslipidemia
• Exhibit 2-14: Physician Ranking of Dyslipidemia Companies
• Exhibit 2-15: Influencing Factors Among Physician' s Perception of a Company in Dyslipidemia
• Exhibit 2-16: Physician Ranking of Preference for First-Line Antidyslipidemics
• Exhibit 2-17: Physician Ranking of Information Channels for Dyslipidemia Drug Treatment
• Exhibit 2-18: Physician Ranking of the Most Popular Information Sources Sought by Patients
• Exhibit 2-19: Summary of Pfizer' s Cardiovascular Portfolio
• Exhibit 2-20: Physician Perception of Pfizer in Dyslipidemia
• Exhibit 2-21: Lipitor' s Key Facts
• Exhibit 2-22: Lipitor' s Expanded Indications
• Exhibit 2-23: Timeline of Lipitor' s Development
• Exhibit 2-24: Physician Perception of Lipitor
• Exhibit 2-25: Physician Response to the Label Expansion of Lipitor
• Exhibit 2-26: Ongoing and Emerging Clinical Trials with Lipitor
• Exhibit 2-27: Lipitor Market ($US), 2006-2011
• Exhibit 2-28: Lipitor Market ($US), by Country, 2006-2011
• Exhibit 2-29: Price to Treat per Day ($US), Lipitor, by Country, 2006
• Exhibit 2-30: Caduet' s Key Facts
• Exhibit 2-31: Timeline of Caduet' s Development
• Exhibit 2-32: Physician Perception of Caduet
• Exhibit 2-33: Ongoing Trials with Caduet
• Exhibit 2-34: Caduet Market ($US), 2006-2011
• Exhibit 2-35: Caduet Market ($US), by Country, 2006-2011
• Exhibit 2-36: Price to Treat per Day ($US), Caduet, by Country
• Exhibit 2-37: Summary of Merck' s Cardiovascular Portfolio
• Exhibit 2-38: Merck Royalties from Astra AP Joint Venture
• Exhibit 2-39: Physician Perception of Merck in Dyslipidemia
• Exhibit 2-40: Zocor' s Key Facts
• Exhibit 2-41: Zocor' s Expanded Indications
• Exhibit 2-42: Timeline of Zocor' s Development
• Exhibit 2-43: Physician Perception of Zocor
• Exhibit 2-44: Zocor Market ($US), 2006-2011
• Exhibit 2-45: Zocor Market ($US), by Country, 2006-2011
• Exhibit 2-46: Price to Treat per Day ($US), Zocor, by Country, 2006
• Exhibit 2-47: Zetia' s Key Facts
• Exhibit 2-48: Timeline of Zetia' s Development
• Exhibit 2-49: Physician Perception of Zetia
• Exhibit 2-50: Emerging Cholesterol Absorption Inhibitors
• Exhibit 2-51: Zetia Market ($US), 2006-2011
• Exhibit 2-52: Zetia Market ($US), by Country, 2006-2011
• Exhibit 2-53: Price to Treat per Day ($US), Zetia, by Country, 2006
• Exhibit 2-54: Vytorin' s Key Facts
• Exhibit 2-55: Timeline of Vytorin' s Development
• Exhibit 2-56: Physician Perception of Vytorin
• Exhibit 2-57: Ongoing Clinical Trials for Vytorin
• Exhibit 2-58: Ongoing Clinical Trials for Vytorin (Continued)
• Exhibit 2-59: Vytorin Market ($US), 2006-2011
• Exhibit 2-60: Vytorin Market ($US), by Country, 2006-2011
• Exhibit 2-61: Price to Treat per Day ($US), Vytorin, by Country, 2006
• Exhibit 2-62: PCPs Perception on the Impact of Cordaptive in the Dyslipidemia Market
• Exhibit 2-63: Cardiologists' Perception on the Impact of Cordaptive in the Dyslipidemia Market
• Exhibit 2-64: Physician Ranking of Emerging Drugs
• Exhibit 2-65: Cordaptive Market ($US), 2006-2011
• Exhibit 2-66: Cordaptive Market ($US), by Country, 2006-2011
• Exhibit 2-67: Expected Price to Treat per Day ($US), Cordaptive, by Country
• Exhibit 2-68: PCPs Perception of MK-0524B
• Exhibit 2-69: Cardiologists Perception of MK-0524B
• Exhibit 2-70: MK-0524B Market ($US), 2006-2011
• Exhibit 2-71: MK-0524B Market ($US), by Country, 2006-2011
• Exhibit 2-72: Expected Price to Treat per Day ($US), MK-0524B, by Country
• Exhibit 2-73: Summary of Schering-Plough' s Cardiovascular Portfolio
• Exhibit 2-74: Physician Perception of Schering-Plough
• Exhibit 2-75: Summary of Abbott' s Cardiovascular Portfolio
• Exhibit 2-76: Physician Perception of Abbott' s Cholesterol Franchise
• Exhibit 2-77: Tricor' s Key Facts
• Exhibit 2-78: Timeline of Tricor' s Development
• Exhibit 2-79: Physician Perception of Tricor
• Exhibit 2-80: Ongoing Clinical Trials for Tricor
• Exhibit 2-81: Tricor Market ($US), 2006-2011
• Exhibit 2-82: Tricor Market ($US), by Country, 2006-2011
• Exhibit 2-83: Price to Treat per Day ($US), Tricor, by Country
• Exhibit 2-84: Niaspan' s Key Facts
• Exhibit 2-85: Timeline of Niaspan' s Development
• Exhibit 2-86: Physician Perception of Niaspan
• Exhibit 2-87: Ongoing Clinical Trials for Niaspan
• Exhibit 2-88: Niaspan Market ($US), 2006-2011
• Exhibit 2-89: Niaspan Market ($US), by Country, 2006-2011
• Exhibit 2-90: Price to Treat per Day ($US), Niaspan, by Country
• Exhibit 2-91: Advicor Market ($US), 2006-2011
• Exhibit 2-92: Advicor Market ($US), by Country, 2006-2011
• Exhibit 2-93: Price to Treat per Day ($US), Advicor, by Country
• Exhibit 2-94: Simcor Market ($US), 2006-2011
• Exhibit 2-95: Simcor Market ($US), by Country, 2006-2011
• Exhibit 2-96: Expected Price to Treat per Day ($US), Simcor, by Country
• Exhibit 2-97: PCPs Perception on the Impact of Crestor/ABT-335 in the Dyslipidemia Market
• Exhibit 2-98: Cardiologists Perception on the Impact of Crestor/ABT-335 in the Dyslipidemia Market
• Exhibit 2-99: Crestor/ABT-335 Market ($US), 2006-2011
• Exhibit 2-100: Crestor/ABT-335 Market ($US), by Country, 2006-2011
• Exhibit 2-101: Expected Price to Treat per Day ($US), Crestor/ABT-335, by Country
• Exhibit 2-102: Summary of AstraZeneca' s Cardiovascular Portfolio
• Exhibit 2-103: Physician Perception of AstraZeneca in Dyslipidemia
• Exhibit 2-104: Crestor' s Key Facts
• Exhibit 2-105: Timeline of Crestor' s Development
• Exhibit 2-106: Physician Perception of Crestor
• Exhibit 2-107: Summary of Completed and Ongoing Studies Investigating Crestor' s Efficacy
• Exhibit 2-108: Summary of Ongoing Trials in the Galaxy Program Targeted to Determine Crestor' s Safety
• Exhibit 2-109: Summary of Completed Trials in the Galaxy Program Targeting Atherosclerosis
• Exhibit 2-110: Summary of Ongoing Galaxy Program Trials Focused in Risk Reduction of CVD
• Exhibit 2-111: Crestor Market ($US), 2006-2011
• Exhibit 2-112: Crestor Market ($US), by Country, 2006-2011
• Exhibit 2-113: Price to Treat per Day ($US), Crestor, by Country
• Exhibit 2-114: Summary of Novartis' s Cardiovascular Portfolio
• Exhibit 2-115: Physician Perception of Novartis in Dyslipidemia
• Exhibit 2-116: Lescol Market ($US), 2006-2011
• Exhibit 2-117: Lescol Market ($US), by Country, 2006-2011
• Exhibit 2-118: Price to Treat per Day ($US), Lescol, by Country
• Exhibit 2-119: Summary of BMS' s Cardiovascular Portfolio
• Exhibit 2-120: Physician Perception of BMS in Dyslipidemia
• Exhibit 2-121: Physician Perception of Pravachol
• Exhibit 2-122: Pravachol Market ($US), 2006-2011
• Exhibit 2-123: Pravachol Market ($US), by Country, 2006-2011
• Exhibit 2-124: Price to Treat per Day ($US), Pravachol, by Country
• Exhibit 2-125: Site of Squalene Synthase Inhibition
• Exhibit 2-126: Lapaquistat Market ($US), 2006-2011
• Exhibit 2-127: Lapaquistat Market ($US), by Country, 2006-2011
• Exhibit 2-128: Expected Price to Treat per Day ($US), Lapaquistat, by Country
• Exhibit 2-129: PCPs Perception on the Impact of ISIS-301012 in Dyslipidemia
• Exhibit 2-130: Cardiologists Perception on the Impact of ISIS-301012 in Dyslipidemia
• Exhibit 2-131: ISIS-301012 Market ($US), 2006-2011
• Exhibit 2-132: ISIS-301012 Market ($US), by Country, 2006-2011
• Exhibit 2-133: Expected Price to Treat per Day ($US), ISIS-301012, by Country

Section 3: Market Forecast

• Exhibit 3-1: Dyslipidemia Market ($US), Major Markets, 2006-2011 (Tabular Format)
• Exhibit 3-2: Dyslipidemia Market ($US), Major Markets, 2006-2011 (Graphical Format)
• Exhibit 3-3: Key Events in Dyslipidemia Market, 2006-2011
• Exhibit 3-4: Dyslipidemia Market ($US), by Country, 2006-2011
• Exhibit 3-5: Dyslipidemia ($US), by Drug Class, 2006-2011
• Exhibit 3-6: Dyslipidemia ($US), by Drug Class, 2006-2011 (Continued)
• Exhibit 3-7: Dyslipidemia Market, by Drug Class, as a % of Total, 2006 and 2011
• Exhibit 3-8: Statin Market ($US), by Drug, 2006-2011
• Exhibit 3-9: Statin Market ($US), by Country, 2006-2011
• Exhibit 3-10: Stain Market ($US), by Brand, 2006-2011
• Exhibit 3-11: Stain Market ($US), by Brand, 2006-2011 (Continued)
• Exhibit 3-12: FDC ($US), by Drug, 2006-2011
• Exhibit 3-13: FDC Market ($US), by Country, 2006-2011
• Exhibit 3-14: FDC Market ($US), by Brand, 2006-2011
• Exhibit 3-15: FDC ($US), by Brand, 2006-2011 (Continued)
• Exhibit 3-16: Zetia Market ($US), 2006-2011
• Exhibit 3-17: Zetia Market ($US), by Country, 2006-2011
• Exhibit 3-18: Fibrate Market ($US), 2006-2011
• Exhibit 3-19: Fibrate Market ($US), by Country, 2006-2011
• Exhibit 3-20: Fibrate Market ($US), by Brand, 2006-2011
• Exhibit 3-21: Fibrate Market ($US), by Brand, 2006-2011 (Continued)
• Exhibit 3-22: Niacin Market ($US), 2006-2011
• Exhibit 3-23: Niacin Market ($US), by Country, 2006-2011
• Exhibit 3-24: Bile Acid Sequestrants ($US), by Drug, 2006-2011
• Exhibit 3-25: Bile Acid Sequestrants Market ($US), by Country, 2006-2011
• Exhibit 3-26: Bile Acid Sequestrants Market ($US), by Brand, 2006-2011
• Exhibit 3-27: Bile Acid Sequestrants Market ($US), by Brand, 2006-2011 (Continued)
• Exhibit 3-28: Omega-3 Acid Ethyl Esters Market ($US), 2006-2011
• Exhibit 3-29: Omega-3 Acid Ethyl Esters Market ($US), by Country, 2006-2011

Section 4: Appendix

• Exhibit 4-1: Adjusted Price of Zocor, 2006-2011
• Exhibit 4-2: Adjusted Price of Lipitor 2006-2011
• Exhibit 4-3: Adjusted Price of Lescol, 2006-2011
• Exhibit 4-4: Surveyed Physicians' Years of Practice
• Exhibit 4-5: Surveyed Physicians' Patients per Month